In order to achieve our goal of providing reliable therapeutic modalities for patients suffering from cancer, we are committed to developing and commercializing adoptive cell therapies utilizing switchable CAR-T (sCAR-T) technology via close collaboration with competent partners who have deep expertise and extensive experience in the field of cellular immunotherapy.
We aim to develop commercial pipelines by fostering synergies through close
collaboration with leading partners in academia and industry.
Exploration and development of new antibodies for switch molecules
Development of advanced sCAR-T
Clinical development with switch molecules and sCAR-T
